You are viewing the site in preview mode

Skip to main content

Table 1 Clinical characteristics of TSHomas with concurrent thyroid cancer reported in literature and present cases

From: A challenging TSH/GH co-secreting pituitary adenoma with concomitant thyroid cancer; a case report and literature review

Reference Age/Sex Pituitary tumor Thyroid cancer Pre-op management The order of surgeries Radio-iodine ablation therapy Preparation (dose) TSH level at the last follow up Clinical outcome
Size (cm) Secreting hormone Histologic type Size (cm), multifocality TNM stage 1st surgery 2nd surgery Pituitary tumor Thyroid cancer
Calle-Pascual [7] et al 55/M NR TSH FTC 5.0 NR No TT TSA&TR NR (35 mCi) Undetectable on LT4 Remission (1 year) Remission (1 year)
Gasparoni [19] et al 37/F 1.0 TSH PTC, 2.0 T2N0M0 No TT No surgery for pituitary tumor NR (150 mCi) NR Remission (NR) NR
Kishida [21] et al 27/F 1.0 TSH PTC 3.0 T2N1M0 Octreotide TSA&TR Lobectomy No Normal range without LT4 NR Remission (9 months)
Ohta [18] et al 45/F 1.5 TSH PTC 2.0 NR Octreotide TT TR via right pterional approach No Normal range Remission (4 months) NR
Gessl [20] et al 22/F 0.4 TSH/PRL FTC 0.8 T1N0M0 No TT TSA&TR NR (80 mCi) 0.6 mU/L Remission (NR) NR
Poggi [8] et al 50/M 0.3 TSH FTC 1.7 NR No TT No surgery for pituitary tumor No 6.97 uIU/mL NR Remission (12 months)
Nguyen [17] et al 57/F 2.6 TSH/GH PTC 0.8, multifocal NR Octreotide TT No surgery for pituitary tumor rhTSH (100 mCi) 0.145 mIU/L Remission (20 months) Octreotide response
Ünlütürk [23] et al 38/F 2.2 TSH PTC, Oncocytic variant 4.0, multifocal T3N1M0 Octreotide TT TSA&TR - > gamma knife surgery NR (150 mCi) 3.4 ~ 3.7 mU/L Stable residual tumor Remission (84 months)
27/F 2.8 TSH PTC 1.0, multifocal T1N0M0 Methimazole TT None NR (150 mCi) 4.7 mU/L Residual tumor on lanreotide Remission (6 months)
Perticone [14] et al 47/M 1.9 TSH FTC, Hürthle cell variant 1.5 T1bN0M0 Lanreotide TT TSA&TR rh TSH (106 mCi) 0.1 mU/L Remission (6 months) Remission (1 year)
46/M 0.7 TSH PTC, Follicular variant 1.2 T1bN0M0 Lanreotide TSA&TR TT rh TSH (100 mCi) 0.2 Remission (5 years) Remission (5 years)
42/M 1.2 TSH PTC NR, multifocal T3bN1aM0 No TT TSA&TR NR (100 mCi) < 0.1 and 0.3 Remission (28 months) Remission (28 months)
Present case 59/M 7.0 TSH/GH PTC 0.5, multifocal T1aN1aM0 Octreotide TT TR via interhemispheric approach Levothyroxine withdrawal (180 mCi) 1.99 uIU/ml Residual tumor on lanreotide Remission (44 months)
  1. TSH thyroid stimulating hormone, GH growth hormone, PRL prolactin, PTC papillary thyroid cancer, FTC follicular thyroid cancer, TT total thyroidectomy, TSA & TR trans-sphenoidal approach and tumor removal, NR not reported, rh recombinant human
Back to article page

BMC Endocrine Disorders

ISSN: 1472-6823

Contact us